The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083992" target="_blank" >RIV/00023001:_____/23:00083992 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/23:73619274 RIV/00098892:_____/23:10158026
Result on the web
<a href="https://link.springer.com/article/10.1007/s00210-023-02561-y" target="_blank" >https://link.springer.com/article/10.1007/s00210-023-02561-y</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00210-023-02561-y" target="_blank" >10.1007/s00210-023-02561-y</a>
Alternative languages
Result language
angličtina
Original language name
The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula
Original language description
Heart failure (HF) has been declared as global pandemic and current therapies are still ineffective, especially in patients that develop concurrent cardio-renal syndrome. Considerable attention has been focused on the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway. In the current study, we aimed to investigate the effectiveness of sGC stimulator (BAY41-8543) with the same mode of action as vericiguat, for the treatment of heart failure (HF) with cardio-renal syndrome. As a model, we chose heterozygous Ren-2 transgenic rats (TGR), with high-output heart failure, induced by aorto-caval fistula (ACF). The rats were subjected into three experimental protocols to evaluate short-term effects of the treatment, impact on blood pressure, and finally the long-term survival lasting 210 days. As control groups, we used hypertensive sham TGR and normotensive sham HanSD rats. We have shown that the sGC stimulator effectively increased the survival of rats with HF in comparison to untreated animals. After 60 days of sGC stimulator treatment, the survival was still 50% compared to 8% in the untreated rats. One-week treatment with sGC stimulator increased the excretion of cGMP in ACF TGR (109 +/- 28 nnmol/12 h), but the ACE inhibitor decreased it (-63 +/- 21 nnmol/12 h). Moreover, sGC stimulator caused a decrease in SBP, but this effect was only temporary (day 0: 117 +/- 3; day 2: 108 +/- 1; day 14: 124 +/- 2 mmHg). These results support the concept that sGC stimulators might represent a valuable class of drugs to battle heart failure especially with cardio-renal syndrome, but further studies are necessary.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Naunyn-Schmiedeberg's archives of pharmacology
ISSN
0028-1298
e-ISSN
1432-1912
Volume of the periodical
396
Issue of the periodical within the volume
12
Country of publishing house
US - UNITED STATES
Number of pages
17
Pages from-to
3757-3773
UT code for WoS article
001015575600006
EID of the result in the Scopus database
2-s2.0-85162252872